288 related articles for article (PubMed ID: 19934291)
1. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
3. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
4. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
Li Q; Wang W; Yamada T; Matsumoto K; Sakai K; Bando Y; Uehara H; Nishioka Y; Sone S; Iwakiri S; Itoi K; Utsugi T; Yasumoto K; Yano S
Am J Pathol; 2011 Sep; 179(3):1483-93. PubMed ID: 21763682
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S; Li Q; Wang W; Yamada T; Takeuchi S; Nakataki E; Ogino H; Goto H; Nishioka Y; Sone S
Front Biosci (Landmark Ed); 2011 Jan; 16(2):740-8. PubMed ID: 21196199
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Van TT; Hanibuchi M; Kakiuchi S; Sato S; Kuramoto T; Goto H; Mitsuhashi A; Nishioka Y; Akiyama S; Sone S
Cancer Chemother Pharmacol; 2011 Aug; 68(2):497-504. PubMed ID: 21079960
[TBL] [Abstract][Full Text] [Related]
8. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
10. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
Nakataki E; Yano S; Matsumori Y; Goto H; Kakiuchi S; Muguruma H; Bando Y; Uehara H; Hamada H; Kito K; Yokoyama A; Sone S
Cancer Sci; 2006 Mar; 97(3):183-91. PubMed ID: 16542214
[TBL] [Abstract][Full Text] [Related]
11. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Ogino H; Hanibuchi M; Kakiuchi S; Trung VT; Goto H; Ikuta K; Yamada T; Uehara H; Tsuruoka A; Uenaka T; Wang W; Li Q; Takeuchi S; Yano S; Nishioka Y; Sone S
Mol Cancer Ther; 2011 Jul; 10(7):1218-28. PubMed ID: 21551260
[TBL] [Abstract][Full Text] [Related]
12. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
14. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
Martarelli D; Catalano A; Procopio A; Orecchia S; Libener R; Santoni G
BMC Cancer; 2006 May; 6():130. PubMed ID: 16704740
[TBL] [Abstract][Full Text] [Related]
15. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
[TBL] [Abstract][Full Text] [Related]
18. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
Otsuki T; Nakashima T; Hamada H; Takayama Y; Akita S; Masuda T; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Miyata Y; Miyake M; Kohno N; Okada M; Hattori N
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29519924
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
20. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
